GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients.
Yu L, Huang L, Lin D, Lai X, Wu L, Liao X, Liu J, Zeng Y, Liang L, Zhang G, Wang B, Wu Z, Tao S, Liu Y, Jiao C, Chang LJ, Yang L.
Yu L, et al. Among authors: liu j, liu y.
J Cancer Res Clin Oncol. 2022 Oct;148(10):2643-2652. doi: 10.1007/s00432-021-03839-5. Epub 2021 Nov 1.
J Cancer Res Clin Oncol. 2022.
PMID: 34724115
Free PMC article.
Clinical Trial.